The beneficial effects of Cinnamon in controlling the blood glucose levels in diabetic patient

The effect of Cinnamomum zeylanicum on Glycosylated Haemoglobin as an add-on therapy for diabetic patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

SLCTR

Registry ID

SLCTR/2012/007

Enrollment

Unknown

Registered

2012-06-27

Start date

2012-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellites

Interventions

1.1. The dose finding study/pilot study Patients will be given Cinnamomum zeylanicum dry powder orally as a capsule in addition to their current treatment. The most effective dose with minimum adverse

Eligibility

Inclusion criteria

Inclusion criteria: All patients with diabetes (International Classification of Diseases, 9th revision, code for diabetes) with a HbA1c of =/>7.0% on a laboratory blood draw during the last 6 months.

Exclusion criteria

Exclusion criteria: Age <18 yrs Pregnancy Known allergy to cinnamon End stage renal disease Cirrhosis

Design outcomes

Primary

Measure	Time frame
Change in HbA1c level [At baseline and every 3 months for a total of 15 months per patient]	—

Secondary

Measure	Time frame
Lipid profile [ At baseline and every 3 months ] Urinary Micro albumin level [At baseline and every 6 months] Liver Function test (SGOT,SGPT) [At baseline and every 3 months] Renal function tests (serum creatinine, BU) [At baseline and every 3 months] Blood glucose levels (Fasting Blood Glucose) [At baseline and monthly (For a total of 15 months)] Baseline blood pressure [At baseline and monthly (For a total of 15 months)] Clinical assessment of exercise tolerance (history and ECG) [At baseline and monthly (For a total of 15 months)]	—

Measure

Time frame

Lipid profile [ At baseline and every 3 months ] Urinary Micro albumin level [At baseline and every 6 months] Liver Function test (SGOT,SGPT) [At baseline and every 3 months] Renal function tests (serum creatinine, BU) [At baseline and every 3 months] Blood glucose levels (Fasting Blood Glucose) [At baseline and monthly (For a total of 15 months)] Baseline blood pressure [At baseline and monthly (For a total of 15 months)] Clinical assessment of exercise tolerance (history and ECG) [At baseline and monthly (For a total of 15 months)]

—

Countries

Sri Lanka

Contacts

Public ContactDr. A.M. Panduka Mahamithawa

Probationary lecturer

mahamithawa2000@yahoo.com+94-81-4479822

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026